查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1598431

血栓症药物市场：按药物类别、疾病类型、分销管道划分 - 全球预测 2025-2030

Thrombosis Drug Market by Drug Class (Factor Xa Inhibitor, Heparin, P2Y12 Platelet Inhibitor), Disease Type (Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年血栓症治疗市值为289.3亿美元，预计到2024年将达到306亿美元，复合年增长率为5.84%，到2030年将达到430.6亿美元。

血栓症药物市场包括用于预防和治疗血管血栓的药物，这些血栓会导致深层静脉栓塞症（DVT）、肺动脉栓塞（PE）和中风等疾病。血栓症药物在临床上极为重要，特别是对于接受手术的患者、心房颤动患者以及血栓形成高风险的患者。应用范围跨越医院、专科诊所、居家照护等多种医疗环境，最终使用者为医疗保健专业人员和患者。市场成长主要是由于心血管疾病盛行率的增加、人口老化以及对血栓症疾病认识的提高而推动的。此外，口服抗凝血剂和标靶治疗等药物传递系统的进步也是主要的成长要素。个人化医疗方法和生技药品存在新的商机，可以有效减少副作用并改善治疗结果。然而，市场扩张受到严格法律规范、高昂开发成本以及阻碍药品核准和定价的专利悬崖等因素的阻碍。此外，与抗凝血剂相关的併发症（例如出血风险）也是局限性的。儘管存在这些挑战，市场仍然存在巨大的创新潜力，包括开发更安全的下一代抗凝血剂以及整合人工智慧主导的诊断以更好地进行患者分层等。您可以利用全面的患者资料来提供真实世界的证据，并透过快速成长的医疗基础设施进入开拓的市场，从而推动成长。与生技公司的合作以及针对新药机制的研发投资也将在克服市场障碍方面发挥关键作用。整体而言，血栓症药物市场充满活力，在更安全、更有效的治疗选择方面还有很大的研发空间。

主要市场统计
基准年[2023] 289.3亿美元
预测年份 [2024] 306亿美元
预测年份 [2030] 430.6亿美元
复合年增长率（%） 5.84%

市场动态：揭示快速发展的血栓症药物市场的关键市场洞察

供需的动态交互作用正在改变血栓症药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 提高患者对血栓症治疗的认识
    • 肾臟疾病、中风和高血压的盛行率飙升
    • 有利的药品报销方案
  • 市场限制因素
    • 药物和治疗费用上涨
  • 市场机会
    • 治疗技术的进步和零售药局的增加
    • 增加医疗支出和增加协作活动
  • 市场挑战
    • 严格的药品监管体系

波特五力：驾驭血栓症药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解血栓症药物市场的外部影响

外部宏观环境因素对血栓症治疗药物市场的表现动态起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解血栓症治疗药物市场竞争状况

对血栓症治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位基质血栓症治疗市场供应商的绩效评估

FPNV定位矩阵是评估血栓症治疗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，绘製血栓症治疗市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，对血栓症治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 提高患者对血栓症治疗的认识
      • 肾臟疾病、中风和高血压的发生率飙升
      • 有利的药品报销方案
    • 抑制因素
      • 药物和治疗费用高昂
    • 机会
      • 治疗技术进步与零售药局的兴起
      • 医疗费用增加和关节活动增加
    • 任务
      • 严格的药品管制制度
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依药物类别血栓症药物市场

  • Xa因子抑制剂
  • 肝素
  • P2Y12血小板抑制剂

第七章血栓症治疗药物市场：依疾病类型

  • 心房颤动
  • 深层静脉栓塞症
  • 肺动脉栓塞

第八章血栓症治疗药物市场：按分销管道

  • 医院药房
  • 网路药房
  • 零售药房

第九章北美和南美血栓症治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区血栓症治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲血栓症治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Aspen Pharmacare Holdings Limited by Mylan NV
  • Aurobindo Pharmaceuticals USA, Inc.
  • B. Braun Melsungen AG
  • Bayer AG
  • Becton, Dickinson and Company
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb
  • Cardinal Health, Inc.
  • GoodRx Holdings, Inc.
  • Grifols, SA
  • Inari Medical, Inc.
  • ITALFARMACO SpA
  • Johnson & Johnson Services, Inc.
  • Pfizer, Inc
  • Sanofi SA
Product Code: MRR-030298DFFFC8

The Thrombosis Drug Market was valued at USD 28.93 billion in 2023, expected to reach USD 30.60 billion in 2024, and is projected to grow at a CAGR of 5.84%, to USD 43.06 billion by 2030.

The thrombosis drug market encompasses medications used for the prevention and treatment of blood clots within blood vessels, which can lead to conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), and strokes. Thrombosis drugs are crucial in clinical settings, especially for patients undergoing surgeries, with atrial fibrillation, or those at high risk of clot formation. The application scope spans multiple healthcare settings, including hospitals, specialized clinics, and homecare settings, with end-users comprising healthcare professionals and patients. The market's growth is primarily driven by the increasing prevalence of cardiovascular diseases, an aging population, and heightened awareness of thrombosis disorders. Additionally, advancements in drug delivery systems, such as oral anticoagulants and targeted therapies, are significant growth influencers. Emerging opportunities lie in personalized medicine approaches and innovations in biologics, effectively reducing side effects and enhancing therapeutic outcomes. However, market expansion is hindered by factors such as stringent regulatory frameworks, high developmental costs, and patent cliffs challenging drug approvals and pricing. Furthermore, complications such as bleeding risks associated with anticoagulants pose limitations. Despite these challenges, the market offers substantial potential for innovation, particularly in developing safer, next-generation anticoagulants and integrating AI-driven diagnostics for better patient stratification. Leveraging comprehensive patient data to inform real-world evidence and expanding into underserved markets with burgeoning healthcare infrastructure can bolster growth. Collaborations with biotechnology firms and investments in R&D focusing on novel drug mechanisms can also play crucial roles in overcoming market barriers. Overall, the thrombosis drugs market is dynamic, with enormous scope for research and development directed toward safer and more effective therapeutic options.

KEY MARKET STATISTICS
Base Year [2023] USD 28.93 billion
Estimated Year [2024] USD 30.60 billion
Forecast Year [2030] USD 43.06 billion
CAGR (%) 5.84%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Thrombosis Drug Market

The Thrombosis Drug Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing patient awareness regarding thrombosis treatment
    • Surge in prevalence of kidney diseases, stroke, and hypertension
    • Favorable reimbursement scenario for the drugs
  • Market Restraints
    • High cost of the medicines and treatment
  • Market Opportunities
    • Technological advancements in the treatment and increasing number of retail pharmacies
    • Growing healthcare expenditure and rise of collaborative activities
  • Market Challenges
    • Strict drug regulatory systems

Porter's Five Forces: A Strategic Tool for Navigating the Thrombosis Drug Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Thrombosis Drug Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Thrombosis Drug Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Thrombosis Drug Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Thrombosis Drug Market

A detailed market share analysis in the Thrombosis Drug Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Thrombosis Drug Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Thrombosis Drug Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Thrombosis Drug Market

A strategic analysis of the Thrombosis Drug Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Thrombosis Drug Market, highlighting leading vendors and their innovative profiles. These include Aspen Pharmacare Holdings Limited by Mylan N.V., Aurobindo Pharmaceuticals USA, Inc., B. Braun Melsungen AG, Bayer AG, Becton, Dickinson and Company, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Cardinal Health, Inc., GoodRx Holdings, Inc., Grifols, S.A, Inari Medical, Inc., ITALFARMACO S.p.A, Johnson & Johnson Services, Inc., Pfizer, Inc, and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the Thrombosis Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Factor Xa Inhibitor, Heparin, and P2Y12 Platelet Inhibitor.
  • Based on Disease Type, market is studied across Atrial Fibrillation, Deep Vein Thrombosis, and Pulmonary Embolism.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing patient awareness regarding thrombosis treatment
      • 5.1.1.2. Surge in prevalence of kidney diseases, stroke, and hypertension
      • 5.1.1.3. Favorable reimbursement scenario for the drugs
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of the medicines and treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in the treatment and increasing number of retail pharmacies
      • 5.1.3.2. Growing healthcare expenditure and rise of collaborative activities
    • 5.1.4. Challenges
      • 5.1.4.1. Strict drug regulatory systems
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Thrombosis Drug Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Factor Xa Inhibitor
  • 6.3. Heparin
  • 6.4. P2Y12 Platelet Inhibitor

7. Thrombosis Drug Market, by Disease Type

  • 7.1. Introduction
  • 7.2. Atrial Fibrillation
  • 7.3. Deep Vein Thrombosis
  • 7.4. Pulmonary Embolism

8. Thrombosis Drug Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Americas Thrombosis Drug Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Thrombosis Drug Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Thrombosis Drug Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Aspen Pharmacare Holdings Limited by Mylan N.V.
  • 2. Aurobindo Pharmaceuticals USA, Inc.
  • 3. B. Braun Melsungen AG
  • 4. Bayer AG
  • 5. Becton, Dickinson and Company
  • 6. Boehringer Ingelheim GmbH
  • 7. Bristol-Myers Squibb
  • 8. Cardinal Health, Inc.
  • 9. GoodRx Holdings, Inc.
  • 10. Grifols, S.A
  • 11. Inari Medical, Inc.
  • 12. ITALFARMACO S.p.A
  • 13. Johnson & Johnson Services, Inc.
  • 14. Pfizer, Inc
  • 15. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. THROMBOSIS DRUG MARKET RESEARCH PROCESS
  • FIGURE 2. THROMBOSIS DRUG MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL THROMBOSIS DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. THROMBOSIS DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. THROMBOSIS DRUG MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. THROMBOSIS DRUG MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL THROMBOSIS DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. THROMBOSIS DRUG MARKET DYNAMICS
  • TABLE 7. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY HEPARIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY P2Y12 PLATELET INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ATRIAL FIBRILLATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY PULMONARY EMBOLISM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. THROMBOSIS DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. THROMBOSIS DRUG MARKET, FPNV POSITIONING MATRIX, 2023